BiotechTube
Aramis Biosciences

Aramis Biosciences

San Diego, United States· Est.
aramisbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Aramis Biosciences is a private, clinical-stage biotech targeting the significant unmet need in ocular surface diseases, particularly dry eye disease (DED). The company's approach is rooted in foundational research from Harvard Medical School's Schepens Eye Research Institute, focusing on modulating specific pro-inflammatory T helper cells implicated in DED pathogenesis. Its lead asset, A197, has completed enrollment in a Phase II proof-of-concept trial, with topline data expected in Q1 2023. Aramis is backed by a team of seasoned pharmaceutical executives and renowned scientific advisors, supported by strategic investors like Santen Ventures and Safar Partners.

OphthalmologyImmunology

Technology Platform

Immunomodulation targeting pathogenic T helper cells on the ocular surface for disease-modifying therapy.

Funding History

2
Total raised:$5M
Seed$3.2M
Seed$1.8M

Opportunities

The primary opportunity lies in addressing the massive treatment gap in dry eye disease, where less than 5% of diagnosed patients use an FDA-approved prescription therapy.
A successful disease-modifying agent with a novel mechanism could capture significant market share in this multi-billion dollar market.
Further opportunity exists to expand the immunomodulatory platform to other inflammatory ocular surface conditions.

Risk Factors

The company faces high clinical risk with its lead asset A197 in Phase II trials; failure would be a major setback.
As a single-asset, pre-revenue private company, it is vulnerable to financing challenges and dilution.
It also operates in a competitive DED market dominated by large, established pharmaceutical companies.

Competitive Landscape

The dry eye disease market is competitive, with several FDA-approved products from companies like AbbVie (Restasis, Xiidra), Novartis (Xiidra rights in some regions), and Bausch + Lomb (Lotemax SM). New entrants and novel mechanisms are continually emerging. Aramis's potential differentiation lies in its first-in-class immunomodulatory approach targeting specific T-cell pathways, aiming for disease modification rather than just symptom relief.

More companies in Small Molecule Drugs →More companies in United States →